{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:07:27Z","timestamp":1790316447094,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1157","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Oligometastatic non-small cell lung cancer (OMD NSCLC) has been proposed to bridge the spectrum between non-metastatic and widely metastatic states and is perceived as an opportunity for potential cure if removed. Twelve clinical trials on local treatment have been reported, yet none are conclusive. These trials informed the development of a joint clinical practice guideline by the American &amp; European Societies for Radiation Oncology, which endorses local treatment for OMD NSCLC. However, the heterogeneity between prognostic factors within these trials likely influenced outcomes and can only support guidance at this time. Caution against an uncritical acceptance of the guideline is discussed, as strong recommendations are offered based on expert opinion and inconclusive evidence. The guideline is also examined by a patient\u2019s caregiver, who emphasizes that uncertain evidence impedes shared decision making.<\/jats:p>","DOI":"10.1093\/bjr\/tqae068","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T04:07:42Z","timestamp":1711598862000},"page":"913-919","source":"Crossref","is-referenced-by-count":3,"title":["Is it too early to recommend local treatment in oligometastatic non-small cell lung cancer: a plea for equipoise"],"prefix":"10.1093","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2944-6797","authenticated-orcid":false,"given":"Irfan","family":"Ahmad","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre , New Delhi 110085, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kundan Singh","family":"Chufal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre , New Delhi 110085, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis Andrew","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Illawarra Cancer Care Center , NSW 2500, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Bajpai","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Staffordshire ST5 5BG, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetha","family":"Umesh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre , New Delhi 110085, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashita","family":"Dawer","sequence":"additional","affiliation":[{"name":"Jindal Global Law School, OP Jindal Global University , Haryana 131001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarthak","family":"Tandon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre , New Delhi 110085, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthilkumar","family":"Gandhidasan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Illawarra Cancer Care Center , NSW 2500, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Dua","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Venkateshwar Hospital , New Delhi 110078, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kratika","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre , New Delhi 110085, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munish","family":"Gairola","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research Centre , New Delhi 110085, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"issue":"4","key":"2024050718554201000_tqae068-B1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/COC.0000000000000169","article-title":"Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of &gt;1000 radiation oncologists","volume":"40","author":"Lewis","year":"2017","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2024050718554201000_tqae068-B2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","article-title":"Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases","volume":"113","author":"Pastorino","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"7598","key":"2024050718554201000_tqae068-B3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bmj.39161.403218.AD","article-title":"When professional opinion is not enough","volume":"334","author":"Treasure","year":"2007","journal-title":"BMJ"},{"issue":"5","key":"2024050718554201000_tqae068-B4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"2024050718554201000_tqae068-B5","first-page":"13058","volume-title":"Clinical Practice Guidelines We Can Trust","author":"Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services, Institute of Medicine","year":"2011"},{"issue":"1-2","key":"2024050718554201000_tqae068-B6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.31128\/AJGP-09-18-4714","article-title":"The role of clinical guidelines in establishing competent professional practice","volume":"48","author":"Pakchung","year":"2019","journal-title":"Aust J Gen Pract"},{"issue":"4","key":"2024050718554201000_tqae068-B7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"2024050718554201000_tqae068-B8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation\u2014determinants of a recommendation\u2019s direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2024050718554201000_tqae068-B9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1258\/135581906777641659","article-title":"A systematic review of factors affecting the judgments produced by formal consensus development methods in health care","volume":"11","author":"Hutchings","year":"2006","journal-title":"J Health Serv Res Policy"},{"issue":"6","key":"2024050718554201000_tqae068-B10","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1215\/03616878-1460524","article-title":"Motivated reasoning and public opinion","volume":"36","author":"Strickland","year":"2011","journal-title":"J Health Polit Policy Law"},{"issue":"11","key":"2024050718554201000_tqae068-B11","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-152-11-201006010-00254","article-title":"The vexing problem of guidelines and conflict of interest: a potential solution","volume":"152","author":"Guyatt","year":"2010","journal-title":"Ann Intern Med"},{"issue":"9686","key":"2024050718554201000_tqae068-B12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(09)60787-X","article-title":"Clinical experts or methodologists to write clinical guidelines?","volume":"374","author":"Hirsh","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"2024050718554201000_tqae068-B13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2018.06.400","article-title":"Long-term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer","volume":"102","author":"Petty","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050718554201000_tqae068-B14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2019.02.006","article-title":"Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study","volume":"130","author":"Arrieta","year":"2019","journal-title":"Lung Cancer"},{"issue":"10","key":"2024050718554201000_tqae068-B15","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mdu370","article-title":"Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients","volume":"25","author":"Collen","year":"2014","journal-title":"Ann Oncol"},{"key":"2024050718554201000_tqae068-B16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2020.12.029","article-title":"Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study","volume":"152","author":"Blake-Cerda","year":"2021","journal-title":"Lung Cancer"},{"key":"2024050718554201000_tqae068-B17","doi-asserted-by":"crossref","first-page":"109681","DOI":"10.1016\/j.radonc.2023.109681","article-title":"EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study","volume":"184","author":"Peng","year":"2023","journal-title":"Radiother Oncol"},{"issue":"12","key":"2024050718554201000_tqae068-B18","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jtho.2018.07.098","article-title":"Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450)","volume":"13","author":"De Ruysscher","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2024050718554201000_tqae068-B19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14218\/JCTH.2023.00188","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"12","author":"Chen","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"9","key":"2024050718554201000_tqae068-B20","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non\u2013small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"2024050718554201000_tqae068-B21","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/JTO.0000000000000673","article-title":"The IASLC Lung Cancer Staging Project","volume":"10","author":"Eberhardt","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2024050718554201000_tqae068-B22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ijrobp.2015.08.012","article-title":"Three-dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage IV non-small cell lung cancer: results of a multicenter phase 2 study from PPRA-RTOG, China","volume":"93","author":"Su","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"2024050718554201000_tqae068-B23","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024050718554201000_tqae068-B24","doi-asserted-by":"crossref","first-page":"e173501-NA","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"34","key":"2024050718554201000_tqae068-B25","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","article-title":"Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non\u2013small-cell lung cancer","volume":"32","author":"Iyengar","year":"2014","journal-title":"J Clin Oncol"},{"key":"2024050718554201000_tqae068-B26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.radonc.2019.11.010","article-title":"Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: a systematic review and meta-analysis of multidisciplinary approaches","volume":"144","author":"Singh","year":"2020","journal-title":"Radiother Oncol"},{"issue":"3","key":"2024050718554201000_tqae068-B27","first-page":"CD010383","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Lung Cancer Group, ed","volume":"3","author":"Greenhalgh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"5586","key":"2024050718554201000_tqae068-B28","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/264542a0","article-title":"Predicting the course of Gompertzian growth","volume":"264","author":"Norton","year":"1976","journal-title":"Nature"},{"issue":"5","key":"2024050718554201000_tqae068-B29","doi-asserted-by":"crossref","first-page":"101221","DOI":"10.1016\/j.adro.2023.101221","article-title":"Is oligometastatic cancer curable? A survey of oncologist perspectives, decision making, and communication","volume":"8","author":"Cho","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"2024050718554201000_tqae068-B30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-981-16-0143-9_13","volume-title":"Decision Making in Emergency Medicine","author":"Musiienko","year":"2021"},{"issue":"8","key":"2024050718554201000_tqae068-B31","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101: stereotactic body radiation therapy: the report of TG101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"issue":"6","key":"2024050718554201000_tqae068-B32","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaoncol.2021.0687","article-title":"Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: findings from the NRG-BR001 phase 1 trial","volume":"7","author":"Chmura","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"2024050718554201000_tqae068-B33","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/1097-0142(19840615)53:12<2736::AID-CNCR2820531233>3.0.CO;2-W","article-title":"Cancer patients\u2019 insight into their treatment, prognosis, and unconventional therapies","volume":"53","author":"Eidinger","year":"1984","journal-title":"Cancer"},{"issue":"21","key":"2024050718554201000_tqae068-B34","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/jama.279.21.1709","article-title":"Relationship between cancer patients\u2019 predictions of prognosis and their treatment preferences","volume":"279","author":"Weeks","year":"1998","journal-title":"JAMA"},{"issue":"4","key":"2024050718554201000_tqae068-B35","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ecc.12425","article-title":"Preferences of lung cancer patients for treatment and decision-making: a systematic literature review","volume":"25","author":"Schmidt","year":"2016","journal-title":"Eur J Cancer Care"},{"issue":"1","key":"2024050718554201000_tqae068-B36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00520-016-3408-7","article-title":"Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits","volume":"25","author":"Fallowfield","year":"2017","journal-title":"Support Care Cancer"},{"issue":"7","key":"2024050718554201000_tqae068-B37","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.pec.2020.11.032","article-title":"Shared decision making: what is the work?","volume":"104","author":"Elwyn","year":"2021","journal-title":"Patient Educ Couns"},{"issue":"9165","key":"2024050718554201000_tqae068-B38","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0140-6736(99)00085-9","article-title":"Chaos surrounds high-dose chemotherapy for breast cancer","volume":"353","author":"The Lancet","year":"1999","journal-title":"The Lancet"},{"issue":"16_suppl","key":"2024050718554201000_tqae068-B39","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"JCO"},{"issue":"10","key":"2024050718554201000_tqae068-B40","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1200\/JCO.1994.12.10.2229","article-title":"Karnofsky Memorial Lecture. Natural history of small breast cancers","volume":"12","author":"Hellman","year":"1994","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqae068\/57262507\/tqae068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqae068\/57445317\/tqae068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqae068\/57445317\/tqae068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T18:56:04Z","timestamp":1715108164000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/97\/1157\/913\/7636460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":40,"journal-issue":{"issue":"1157","published-online":{"date-parts":[[2024,3,27]]},"published-print":{"date-parts":[[2024,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqae068","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,3,27]]}}}